Fowkes FGR, Rudan D, Rudan I, Aboyans V, Denenberg JO, McDermott MM, Norman PE, Sampson UKA, Williams LJ, Mensah GA, Criqui MH. Comparison of global estimates of prevalence and risk factors for peripheral artery disease in 2000 and 2010: A systematic review and analysis. Lancet. 2013;382(9901):1329–40. https://doi.org/10.1016/S0140-6736(13)61249-0.

Article  PubMed  Google Scholar 

Criqui MH, Aboyans V. Epidemiology of peripheral artery disease. Circul Res. 2015;116(9):1509–26. https://doi.org/10.1161/CIRCRESAHA.116.303849.

Article  CAS  Google Scholar 

Jude EB, Eleftheriadou I, Tentolouris N. Peripheral arterial disease in diabetes—A review. Diabet Med. 2010;27(1):4–14. https://doi.org/10.1111/j.1464-5491.2009.02866.x.

Article  CAS  PubMed  Google Scholar 

Mahé G, Aboyans V, Cosson E, Bernard M, Valensi P, Potier L. Challenges and opportunities in the management of type 2 diabetes in patients with lower extremity peripheral artery disease: A tailored diagnosis and treatment review. Cardiovasc Diabetol. 2024;23(1). https://doi.org/10.1186/s12933-024-02325-9.

McDermott MM. Lower extremity manifestations of peripheral artery disease: The pathophysiologic and functional implications of leg ischemia. Circul Res. 2015;116(9):1540–50. https://doi.org/10.1161/CIRCRESAHA.114.303517.

Article  CAS  Google Scholar 

Gerstein HC, Colhoun HM, Dagenais GR, Diaz R, Lakshmanan M, Pais P, Probstfield J, Riesmeyer JS, Riddle MC, Rydén L, Xavier D, Atisso CM, Dyal L, Hall S, Rao-Melacini P, Wong G, Avezum A, Basile J, Chung N, Bosch J. Dulaglutide and cardiovascular outcomes in type 2 diabetes (REWIND): A double-blind, randomised placebo-controlled trial. Lancet. 2019;394(10193):121–30. https://doi.org/10.1016/S0140-6736(19)31149-3.

Article  CAS  PubMed  Google Scholar 

Marso SP, Bain SC, Consoli A, Eliaschewitz FG, Jódar E, Leiter LA, Lingvay I, Rosenstock J, Seufert J, Warren ML, Woo V, Vilsbøll T, SUSTAIN-6 Investigators. Semaglutide and cardiovascular outcomes in patients with type 2 diabetes. N Engl J Med. 2016;375(19):1834–44. https://doi.org/10.1056/NEJMoa1607141.

Article  CAS  PubMed  Google Scholar 

Dhatariya K, Bain SC, Buse JB, Simpson R, Tarnow L, Kaltoft MS, Stellfeld M, Tornøe K, Pratley RE, LEADER Trial Investigators. The impact of liraglutide on diabetes-related foot ulceration and associated complications in patients with type 2 diabetes at high risk for cardiovascular events: Results from the LEADER trial. Diabetes Care. 2018;41(10):2229–35. https://doi.org/10.2337/dc18-0654.

Article  PubMed  PubMed Central  Google Scholar 

McGuire DK, Marx N, Mulvagh SL, Deanfield JE, Inzucchi SE, Pop-Busui R, Mann JFE, Emerson SS, Poulter NR, Engelmann MDM, Ripa MS, Hovingh GK, Brown-Frandsen K, Bain SC, Cavender MA, Gislum M, David JP, Buse JB, SOUL Study Group. Oral Semaglutide and Cardiovascular Outcomes in High-Risk Type 2 Diabetes. N Engl J Med. 2025;392(20):2001–12. https://doi.org/10.1056/NEJMoa2501006.

Article  CAS  PubMed  Google Scholar 

Bonaca MP, Catarig AM, Houlind K, Ludvik B, Nordanstig J, Ramesh CK, Rasouli N, Sourij H, Videmark A, Verma S, STRIDE Trial Investigators. Semaglutide and walking capacity in people with symptomatic peripheral artery disease and type 2 diabetes (STRIDE): a phase 3b, double-blind, randomised, placebo-controlled trial. Lancet (London England). 2025;405(10489):1580–93. https://doi.org/10.1016/S0140-6736(25)00509-4.

Article  CAS  PubMed  Google Scholar 

Page MJ, McKenzie JE, Bossuyt PM, Boutron I, Hoffmann TC, Mulrow CD, Shamseer L, Tetzlaff JM, Akl EA, Brennan SE, Chou R, Glanville J, Grimshaw JM, Hróbjartsson A, Lalu MM, Li T, Loder EW, Mayo-Wilson E, McDonald S, Moher D. The PRISMA 2020 statement: An updated guideline for reporting systematic reviews. BMJ. 2021;372. https://doi.org/10.1136/bmj.n71. Article n71.

Deeks JJ, Higgins JPT, Altman DG. Analysing data and undertaking meta-analyses. In: Higgins JPT, Thomas J, Chandler J, Cumpston M, Li T, Page MJ, Welch VA, editors. Cochrane handbook for systematic reviews of interventions. 2nd ed. Wiley; 2019. pp. 241–84. https://doi.org/10.1002/9781119536604.ch10.

Sterne JAC, Savović J, Page MJ, Elbers RG, Blencowe NS, Boutron I, Cates CJ, Cheng H-Y, Corbett MS, Eldridge SM, Emberson JR, Hernán MA, Hopewell S, Hróbjartsson A, Junqueira DR, Jüni P, Kirkham JJ, Lasserson T, Li T, Higgins JPT. RoB 2: A revised tool for assessing risk of bias in randomised trials. BMJ. 2019;366. https://doi.org/10.1136/bmj.l4898. Article l4898.

Sterne JAC, Hernán MA, Reeves BC, Savović J, Berkman ND, Viswanathan M, Henry D, Altman DG, Ansari MT, Boutron I, Carpenter JR, Chan AW, Churchill R, Deeks JJ, Hróbjartsson A, Kirkham J, Jüni P, Loke YK, Pigott TD, Higgins JPT. ROBINS-I: A tool for assessing risk of bias in non-randomised studies of interventions. BMJ. 2016;355. https://doi.org/10.1136/bmj.i4919. Article i4919.

Mantel N, Haenszel W. Statistical aspects of the analysis of data from retrospective studies of disease. J Natl Cancer Inst. 1959;22(4):719–48. https://doi.org/10.1093/jnci/22.4.719.

Article  CAS  PubMed  Google Scholar 

Higgins JPT, Thompson SG, Deeks JJ, Altman DG. Measuring inconsistency in meta-analyses. BMJ. 2003;327(7414):557–60. https://doi.org/10.1136/bmj.327.7414.557.

Article  PubMed  PubMed Central  Google Scholar 

Corbeil RR, Searle SR. Restricted maximum likelihood (REML) estimation of variance components in the mixed model. Technometrics. 1976;18(1):31–8. https://doi.org/10.2307/1267913.

Article  Google Scholar 

Wu JY, Tu WL, Yu T, Liao KM, Lin YM. Tirzepatide and major adverse limb events: Insights from a multicenter real-world analysis in PAD and diabetes patients. Diabetes Res Clin Pract. 2025;222:112083. https://doi.org/10.1016/j.diabres.2025.112083.

Article  CAS  PubMed  Google Scholar 

Lewis JE, Omenge DK, Patterson AR, Anwaegbu O, Tabukum NN, Lewis JE 3rd, Lee WC. The impact of semaglutide on wound healing in diabetes related foot ulcer patients: A TriNetX database study. Diabetes Vasc Dis Res. 2025;22(2):14791641251322909. https://doi.org/10.1177/14791641251322909.

Article  Google Scholar 

Caruso P, Maiorino MI, Longo M, Porcellini C, Matrone R, Digitale Selvaggio L, Gicchino M, Carbone C, Scappaticcio L, Bellastella G, Giugliano D, Esposito K. Liraglutide for Lower Limb Perfusion in People With Type 2 Diabetes and Peripheral Artery Disease: The STARDUST Randomized Clinical Trial. JAMA Netw open. 2024;7(3):e241545. https://doi.org/10.1001/jamanetworkopen.2024.1545.

Article  PubMed  PubMed Central  Google Scholar 

Badjatiya A, Merrill P, Buse JB, Goodman SG, Katona B, Iqbal N, Pagidipati NJ, Sattar N, Holman RR, Hernandez AF, Mentz RJ, Patel MR, Jones WS. Clinical Outcomes in Patients With Type 2 Diabetes Mellitus and Peripheral Artery Disease: Results From the EXSCEL Trial. Circ Cardiovasc Interv. 2019;12(12):e008018. https://doi.org/10.1161/CIRCINTERVENTIONS.119.008018.

Article  PubMed  Google Scholar 

Holman RR, Bethel MA, Mentz RJ, Thompson VP, Lokhnygina Y, Buse JB, Chan JC, Choi J, Gustavson SM, Iqbal N, Maggioni AP, Marso SP, Öhman P, Pagidipati NJ, Poulter N, Ramachandran A, Zinman B, Hernandez AF, EXSCEL Study Group. Effects of Once-Weekly Exenatide on Cardiovascular Outcomes in Type 2 Diabetes. N Engl J Med. 2017;377(13):1228–39. https://doi.org/10.1056/NEJMoa1612917.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Stefanou MI, Theodorou A, Malhotra K, Katsanos AH, Ganesh A, Shoamanesh A, Sharma M, Tsivgoulis G, Turc G. Risk of major adverse cardiovascular events and stroke associated with treatment with GLP-1 or the dual GIP/GLP-1 receptor agonist tirzepatide for type 2 diabetes: A systematic review and meta-analysis. Eur Stroke J. 2024;9(3):530–9. https://doi.org/10.1177/23969873241230549.

Article  PubMed  PubMed Central  Google Scholar 

Garagoli F, Masson W, Barbagelata L, Lobo M. Effect of glucagon-like peptide-1 receptor agonists on the risk of major adverse limb events in patients with type 2 diabetes mellitus: A systematic review and meta-analysis of randomized clinical trials. Endocrinología Diabetes y Nutrición (English Ed). 2025;72(5):501562. https://doi.org/10.1016/j.endien.2024.07.002.

Article  Google Scholar 

Pfeffer MA, Claggett B, Diaz R, Dickstein K, Gerstein HC, Køber LV, Lawson FC, Ping L, Wei X, Lewis EF, Maggioni AP, McMurray JJ, Probstfield JL, Riddle MC, Solomon SD, Tardif JC, ELIXA Investigators. Lixisenatide in patients with type 2 diabetes and acute coronary syndrome. N Engl J Med. 2015;373(23):2247–57. https://doi.org/10.1056/NEJMoa1509225.

Article  CAS  PubMed  Google Scholar 

Reed J, Kanamarlapudi V, Bain S. Mechanism of cardiovascular disease benefit of glucagon-like peptide 1 agonists. Cardiovasc Endocrinol Metabolism. 2018;7(1):18–23. https://doi.org/10.1097/XCE.0000000000000142.

Article  CAS  Google Scholar 

Marx N, Husain M, Lehrke M, Verma S, Sattar N. GLP-1 receptor agonists for the reduction of atherosclerotic cardiovascular risk in patients with type 2 diabetes. Circulation. 2022;146(24):1882–94. https://doi.org/10.1161/CIRCULATIONAHA.122.059595.

Article  CAS  PubMed  Google Scholar 

Anholm C, Kumarathurai P, Pedersen LR, Samkani A, Nielsen JR, Kristiansen OP, Fenger M, Madsbad S, Sajadieh A, Haugaard SB. Liraglutide in combination with metformin may improve the atherogenic lipid profile and decrease C-reactive protein level in statin-treated obese patients with coronary artery disease and newly diagnosed type 2 diabetes: A randomized trial. Atherosclerosis. 2019;288:60–6. https://doi.org/10.1016/j.atherosclerosis.2019.07.007.

Article  CAS  PubMed  Google Scholar